These interactions involve multiple Nef surfaces, complicating medicinal chemistry optimization of occupancy-based drug candidates. To address this issue, we initiated PROTAC development for the ...

Ground-breaking drug discovery work at the University of Dundee has been honoured by a major international award.

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...

The two companies will also share costs and profits from the drug, which will start a phase 3 programme next year. The buy-in is another endorsement of Arvinas' PROTAC drugs, bifunctional ...

In the trial ARV-102, the company’s investigational PROteolysis TArgeting Chimera (PROTAC) leucine-rich repeat ... Also Read: Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free ...

"The first phase 3 data readout for a PROTAC degrader represents a significant ... Menarini/Stemline's Orserdu (elacestrant) was the first drug in the oral SERD class to be cleared by the FDA ...

If the drug cannot show significant improvements in ... Favorable results would not only validate Arvinas’s PROTAC® technology platform but also potentially position vepdegestrant as a best ...

The drug has already been granted fast track designation by the ... “The first phase 3 data readout for a PROTAC degrader represents a significant achievement and this data shows that vepdegestrant ...

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...